Treatment provision and management for the menopause: a multinational survey study
Nayra A Martin-Key1, Erin L Funnell1, Sabine Bahn1
1Department of Chemical Engineering and Biotechnology, Cambridge Centre for Neuropsychiatric Research, University of Cambridge, Cambridge, United Kingdom.
Introduction:
Despite available safe hormonal and non-hormonal interventions, most women with troublesome menopausal symptoms do not receive effective, evidence-based therapy, with notable international disparities in provision. This study aimed to investigate self-reported menopausal care experiences in a self-selecting sample from five English-speaking countries: Australia, Canada, New Zealand, the United Kingdom, and the United States, through an anonymous online survey.
Methods:
The 15-20 min survey, delivered via Qualtrics XM®, included questions on sociodemographic characteristics and treatment experiences, such as the number of healthcare professionals (HCP) seen before getting a prescription, ease of obtaining treatment, involvement in treatment discussions, appropriateness of treatment review and optimization, side effect tolerability, and overall satisfaction.
Results:
Data from 3,062 respondents were analyzed: Australia (16.59%, n = 508), Canada (17.54%, n = 537), New Zealand (16.59%, n = 508), UK (24.00%, n = 735), and US (25.28%, n = 774). Significant international differences were observed in both healthcare access and prescribing patterns. More women in the UK and US consulted an HCP compared with Australia, Canada, and New Zealand [χ²(4, N = 3062) = 101.02, p < 0.001, φc = 0.18]. Prescription rates were higher in New Zealand, the UK, and the US compared with Australia and Canada [χ²(4, N = 2,485) = 75.71, p < 0.001, φc = 0.18]. However, UK respondents, despite longer treatment use, generally reported less involvement in treatment discussions, poorer treatment review, lower side effect tolerability, and reduced satisfaction compared with other countries across treatment types.
Discussion:
Based on a self-selected cohort, these findings reveal critical gaps in menopause care, including disparities in treatment access and international differences in patient involvement. Greater access to healthcare in the UK and the US did not translate into higher satisfaction, highlighting the need for patient-centered approaches. Improving care requires better clinician education and strategies to enhance communication and shared decision-making.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Hormonal Regulation
Hormonal Regulation
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
